The purpose of this study is to assess the effects of 2 doses of LY2189265 on blood pressure and heart rate using 24-hour ambulatory blood pressure monitoring (ABPM), in participants with type 2 diabetes mellitus treated with oral antihyperglycemic medications (OAMs).

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Type 2 diabetes taking 1 or more oral diabetes medications and have taken these medications for at least 1 month prior to screening
Glycosylated hemoglobin (HbA1c) value ≥7% and ≤9.5% at screening
Mean blood pressure \>90/60 millimeters of mercury (mmHg) and \<140/90 mmHg at screening
If treated for hypertension, are taking 3 or less antihypertensive medications and have been taking these medications for at least 1 month prior to screening
Stable weight for 3 months prior to screening
Body mass index (BMI) greater than or equal to 23 kilogram-meter squared (kg/m\^2)
Willing to wear an ambulatory blood pressure monitoring device for at least 24 hours on multiple occasions
Women of childbearing potential must test negative for pregnancy and be willing to use a reliable method of birth control
Male participants must use a reliable method of birth control

Criterios de exclusión

Severe renal impairment
Myocardial infarction, stroke, or hospitalization for heart failure within 3 months prior to screening, or heart failure Class III or IV at screening
Ongoing or history of frequent intermittent tachyarrhythmia
Resting heart rate \<60 beats per minute (bpm) or \>100 bpm at screening
Work rotating shifts or work during the hours of 2200 to 0700
Chronic insulin therapy
Use of a glucagon-like peptide 1 (GLP-1) receptor agonist within 3 months prior to screening, or a dipeptidylpeptidase-IV (DPP-IV) inhibitor within 2 weeks prior to screening
Nondominant arm circumference \>42 centimeter (cm)
Use of drugs to promote weight loss
Chronic use of systemic steroids
Gastric emptying abnormality or bariatric surgery
Hepatitis, other liver disease, or alanine transaminase (ALT) \>3 times the upper limit of normal
Acute or chronic pancreatitis
Active autoimmune disease or uncontrolled endocrine abnormality
Self or family history of thyroid cancer, medullary C-cell hyperplasia, or type 2A or 2B multiple endocrine neoplasia
Calcitonin value greater than or equal to 20 picograms per milliliter (pg/ml) at screening
Transplanted organ except corneal transplants
Active or untreated cancer or in remission \<5 years, except skin, in situ cervical, or prostate cancer
Sickle-cell disease, hemolytic anemia, or another hematological condition that may interfere with HbA1c testing

Ubicaciones

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Buenos Aires, Argentina

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Caba, Argentina

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Mar del Plata, Argentina

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Mendoza, Argentina

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Santa Fe, Argentina

The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus

Resumen

Elegibilidad

Criterios de inclusión

Criterios de exclusión

Intervenciones

LY2189265

Placebo

Ubicaciones

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Patrocinadores